PORTFOLIO NEWS Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim November 29, 2022 Read More » Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration November 29, 2022 Read More » Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy November 28, 2022 Read More » Escient Pharmaceuticals Announces $120 Million Series C Financing November 28, 2022 Read More » Tenaya Therapeutics Announces Closing of Public Offering November 21, 2022 Read More » Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data November 21, 2022 Read More » Escient Pharmaceuticals Initiates Phase 2 Pacific Study Evaluating EP547, an Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus November 17, 2022 Read More » RAPT Therapeutics Announces Pricing of Public Offering of Common Stock November 17, 2022 Read More » Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires November 16, 2022 Read More » Casma Therapeutics Raises $46.0 M in Series C Funding November 15, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim November 29, 2022 Read More »
Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration November 29, 2022 Read More »
Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy November 28, 2022 Read More »
Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data November 21, 2022 Read More »
Escient Pharmaceuticals Initiates Phase 2 Pacific Study Evaluating EP547, an Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus November 17, 2022 Read More »
